Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

In vitro screening for chemokine antagonists.

Ribeiro S, Horuk R.

Expert Opin Drug Discov. 2009 Oct;4(10):1017-34. doi: 10.1517/17460440902956628. Epub 2009 Sep 19.

PMID:
23480395
2.

Small molecule antagonists of chemokine receptors--is promiscuity a virtue?

Pease JE, Horuk R.

Curr Top Med Chem. 2010;10(13):1351-8. Review.

PMID:
20536423
3.

Chemokine receptor antagonists: Part 1.

Pease JE, Horuk R.

Expert Opin Ther Pat. 2009 Jan;19(1):39-58. doi: 10.1517/13543770802641346. Review.

PMID:
19441897
4.

Chemokine blockers--therapeutics in the making?

Wells TN, Power CA, Shaw JP, Proudfoot AE.

Trends Pharmacol Sci. 2006 Jan;27(1):41-7. Epub 2005 Nov 28. Review.

PMID:
16310864
5.

Drug discovery targeting the chemokine system--where are we?

Horuk R, Proudfoot AE.

Front Biosci (Elite Ed). 2009 Jun 1;1:209-19. Review.

PMID:
19482638
6.

Chemokine receptors: multifaceted therapeutic targets.

Proudfoot AE.

Nat Rev Immunol. 2002 Feb;2(2):106-15. Review. Erratum in: Nature Rev Immunol 2002 Mar;2(3):215.

PMID:
11910892
7.

Drug discovery and chemokine receptor antagonists: eppur si muove!

Terricabras E, Benjamim C, Godessart N.

Autoimmun Rev. 2004 Nov;3(7-8):550-6. Review.

PMID:
15546804
8.

Chemokines, chemokine receptors and small-molecule antagonists: recent developments.

Onuffer JJ, Horuk R.

Trends Pharmacol Sci. 2002 Oct;23(10):459-67. Review.

PMID:
12368070
9.

Anti-chemokine small molecule drugs: a promising future?

Proudfoot AE, Power CA, Schwarz MK.

Expert Opin Investig Drugs. 2010 Mar;19(3):345-55. doi: 10.1517/13543780903535867. Review.

PMID:
20113217
10.

Chemokines and their receptors in the central nervous system.

Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G.

Front Neuroendocrinol. 2001 Jul;22(3):147-84. Review.

PMID:
11456467
11.

High content screening for G protein-coupled receptors using cell-based protein translocation assays.

Grånäs C, Lundholt BK, Heydorn A, Linde V, Pedersen HC, Krog-Jensen C, Rosenkilde MM, Pagliaro L.

Comb Chem High Throughput Screen. 2005 Jun;8(4):301-9.

PMID:
16101006
12.

Current status of chemokine receptor inhibitors in development.

Allegretti M, Cesta MC, Garin A, Proudfoot AE.

Immunol Lett. 2012 Jul 30;145(1-2):68-78. doi: 10.1016/j.imlet.2012.04.003. Epub 2012 Apr 20. Review.

PMID:
22698186
13.

Anti-inflammatory drug development: Broad or specific chemokine receptor antagonists?

Russo RC, Garcia CC, Teixeira MM.

Curr Opin Drug Discov Devel. 2010 Jul;13(4):414-27. Review.

PMID:
20597027
14.

The clinical potential of chemokine receptor antagonists.

Ribeiro S, Horuk R.

Pharmacol Ther. 2005 Jul;107(1):44-58. Review.

PMID:
15894378
15.

Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.

Hatse S, Princen K, Liekens S, Vermeire K, De Clercq E, Schols D.

Cytometry A. 2004 Oct;61(2):178-88.

16.

New therapeutics that modulate chemokine networks.

Schwarz MK, Wells TN.

Nat Rev Drug Discov. 2002 May;1(5):347-58. Review.

PMID:
12120410
17.

Chemokine: receptor structure, interactions, and antagonism.

Allen SJ, Crown SE, Handel TM.

Annu Rev Immunol. 2007;25:787-820. Review.

PMID:
17291188
18.

Promiscuous drugs as therapeutics for chemokine receptors.

Horuk R.

Expert Rev Mol Med. 2009 Jan 6;11:e1. doi: 10.1017/S1462399409000921. Review.

PMID:
19123963
19.

The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention.

Cascieri MA, Springer MS.

Curr Opin Chem Biol. 2000 Aug;4(4):420-7. Review.

PMID:
10959770
20.

Viral exploitation and subversion of the immune system through chemokine mimicry.

Murphy PM.

Nat Immunol. 2001 Feb;2(2):116-22. Review.

PMID:
11175803

Supplemental Content

Support Center